XML 47 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 102 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 28, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues $ 26,460 $ 28,563 $ 84,069 $ 82,715  
Novartis Institutes for BioMedical Research, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 9,610 11,514 29,433 28,956  
Novartis Institutes for BioMedical Research, Inc. | Recognition of upfront fee          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 7,582 9,093 23,222 22,852  
Novartis Institutes for BioMedical Research, Inc. | Research services          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 2,028 2,421 6,211 6,104  
Biogen MA, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 9,413 10,967 30,658 32,184  
Biogen MA, Inc. | Recognition of upfront fee          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 7,306 7,306 21,918 21,918  
Biogen MA, Inc. | Research services          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 2,107 3,661 8,740 10,266  
Kite Pharma, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 6,915 6,409 19,557 19,021  
Kite Pharma, Inc. | Recognition of upfront fee          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 6,296 6,296 18,682 18,682  
Kite Pharma, Inc. | Research services          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 619 113 875 339  
Sanofi          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 0 (759) 3,260 1,258 $ 13,500
Sanofi | Recognition of upfront fee          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 0 (1,125) 677 (692)  
Sanofi | Research services          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues 0 1,125 2,126 2,417  
Sanofi | Milestone achievement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues $ 0 $ (759) $ 457 $ (467)